Multi-Cancer Early Detection (MCED) Tests: Molecular Basis, Clinical Performance, and Role in Cancer Screening

Early detection of malignant neoplasms is one of the key factors in reducing cancer-related mortality. However, currently available screening programs cover only a limited number of cancer types and fail to detect the majority of malignancies at the preclinical stage. In recent years, advances in liquid biopsy technologies and next-generation sequencing have led to the development of multi-cancer early detection (MCED) tests based on the analysis of circulating tumor DNA.

MCED tests represent a fundamentally new approach to cancer screening, enabling a single blood test to assess the likelihood of multiple malignancies and, in many cases, identify the most likely tissue of origin. Unlike conventional organ-specific screening methods, these tests rely on the molecular and epigenetic characteristics of tumors, including DNA methylation patterns and genomic fragmentation profiles.

Despite substantial technological advances, the clinical role of MCED testing remains under active investigation. Further evaluation is required regarding sensitivity in early-stage disease, impact on cancer-specific mortality, risks of overdiagnosis, and cost-effectiveness. This article reviews the biological basis of MCED testing, its diagnostic performance, clinical indications, interpretation of test results, and its role within the contemporary framework of cancer screening.

Principles of MCED Testing: Biological Basis and Technologies

Multi-cancer early detection (MCED) tests are based on the analysis of circulating tumor biomarkers in peripheral blood and represent an evolution of the liquid biopsy concept. The primary target of analysis is circulating tumor DNA (ctDNA), which is released into the bloodstream as a result of tumor cell apoptosis and necrosis. Unlike conventional organ-specific screening methods, MCED tests enable simultaneous assessment of the likelihood of multiple types of malignant neoplasms.

DNA Methylation Analysis

One of the most promising technologies underlying MCED testing is DNA methylation analysis. Epigenetic changes, particularly CpG island methylation, are among the earliest events in carcinogenesis and exhibit tissue-specific patterns. This enables not only the detection of an underlying malignant process but also highly accurate prediction of the tissue of origin. Compared with the analysis of individual somatic mutations, DNA methylation profiling demonstrates greater sensitivity when ctDNA concentrations are low, making it especially valuable for the detection of early-stage malignancies.

Technological Base: Next-Generation Sequencing and Machine Learning

Technologically, MCED tests are implemented using next-generation sequencing (NGS) combined with sophisticated machine learning algorithms. Following extraction of cell-free DNA (cfDNA) from plasma, the DNA undergoes sequencing, after which bioinformatic analysis is performed to identify tumor-associated patterns. Classification algorithms compare these findings with reference databases to estimate both the probability of an underlying malignancy and its most likely tissue of origin.

Platform Sensitivity and Multimodal Approaches

An important aspect is the extremely low proportion of ctDNA within the total pool of circulating cell-free DNA, particularly in early-stage disease, where ctDNA may account for less than 0.1 percent. This places stringent demands on the analytical sensitivity of testing platforms as well as on the quality of preanalytical phase. To improve accuracy, many platforms employ multimodal approaches that integrate analysis of DNA mutations, methylation, and fragmentation.

Clinical Potential of Molecular Diagnostics

Taken together, MCED tests are a high-tech molecular diagnostic tool that integrates the advances in genomics, epigenetics, and artificial intelligence. Their principal potential lies in the ability to detect malignant tumors at the preclinical stage, although their clinical relevance and optimal applications continue to be actively investigated.

Clinical Performance of MCED Tests: Sensitivity, Specificity, and Limitations

The clinical performance of MCED tests is determined by their ability to detect malignant neoplasms at an early stage while maintaining an acceptable rate of false-positive results. The key performance characteristics are sensitivity and specificity; however, the interpretation of these metrics in the context of MCED is unique because these tests simultaneously evaluate multiple cancer types.

Specificity and Stage-Dependent Sensitivity

According to prospective studies — most notably the Circulating Cell-free Genome Atlas (CCGA) study, which enrolled more than 15,000 participants and served as the foundation for the development of several commercial MCED platforms — the specificity of DNA methylation-based MCED tests exceeds 99 percent, minimizing the risk of false-positive results and making them potentially suitable for population-based screening. Sensitivity varies substantially depending on tumor stage. For stage I, sensitivity may be below 20–30 percent, whereas for stage III–IV, it exceeds 70–80 percent. This reflects a fundamental limitation of the technology: low concentration of ctDNA during the earliest phases of carcinogenesis.

Influence of Tumor Type on Test Results

Sensitivity also varies according to tumor type. The highest detection rates are observed for malignancies characterized by high biological activity and intense DNA release, such as liver, pancreatic, and lung cancers. Whereas for slow-growing tumors, including certain kidney and thyroid cancers, sensitivity is considerably lower. This creates a risk of inconsistent detection of different types of cancer, limiting the universality of the method.

Accuracy of Tissue-of-Origin Prediction

The ability to predict the tissue of origin is an important advantage of MCED. In several studies, the accuracy of tissue-of-origin prediction has reached 80–90 percent, substantially facilitating subsequent diagnosis. Nevertheless, even with very high specificity, a positive MCED result must always be confirmed using standard diagnostic imaging and histological confirmation.

Current Limitations and Future Implementation

Among the limitations is the absence of evidence demonstrating that MCED testing reduces cancer-related mortality, which is the fundamental criterion to assess the efficiency of any screening program. Most currently available data is based on diagnostic accuracy rather than clinical outcomes. In addition, unresolved issues remain regarding false-positive results, overdiagnosis, and the detection of clinically insignificant tumors.

Although MCED tests demonstrate excellent analytical specificity and represent a highly promising technological advance, their current clinical efficiency is limited by relatively low sensitivity in early-stage disease and the lack of long-term outcome data demonstrating an effect on survival. Their incorporation into routine clinical practice will require additional randomized clinical trials and further evaluation within cancer screening programs.

Indications for MCED Testing: Who Should Be Tested and When

The appropriateness of incorporating MCED testing into routine clinical practice remains a matter of ongoing debate, as no current clinical guidelines recommend its use as a standard population-based screening modality. Nevertheless, several patient groups have been identified in whom MCED testing may offer the greatest potential clinical benefit.

Foremost among these are individuals at increased risk of developing malignancy. This population includes older adults (generally those over 50 years of age), individuals with a strong family history of cancer, carriers of germline mutations (e.g., in BRCA1/2, TP53, MLH1 and others), and patients with premalignant conditions. In this group of patients the risk of an asymptomatic tumor is higher, which theoretically increases the diagnostic value of MCED.

Stratification of Patients by Cancer Risk Level

From a practical standpoint, patients may be stratified into several categories according to their individual risk of developing malignancy, allowing a more evidence-informed approach to the use of MCED testing.

High-risk group:

• Carriers of germline mutations (e.g., BRCA1/2, TP53, MLH1, MSH2, and others);
• Patients with established hereditary cancer syndromes (e.g., Lynch syndrome, Li-Fraumeni syndrome, and others);
• Individuals with a strong family history (two or more relatives with malignancy, particularly involving the same tissue or organ);
• Patients with a history of multiple primary tumors.

This group is most likely to benefit from MCED testing; however, the available evidence remains limited.

Moderate-risk group:

• Adults older than 50 years;
• Individuals with behavioral risk factors (e.g., smoking, obesity, and others);
• Patients with premalignant conditions.

In this group, the diagnostic value may vary considerably and should be assessed on an individual basis.

General population (low risk):

• Individuals without significant cancer risk factors;
• Younger adults.

At present, the use of MCED testing in this population is not recommended outside clinical research, owing to the uncertain balance between potential benefits and harms.

MCED and Standard Cancer Screening Programs

Particular attention should be given to patients not covered by existing screening programs. At present, effective screening strategies are available for only a limited number of malignancies (breast cancer, cervical cancer, colorectal cancer, and lung cancer in smokers). MCED tests have the potential to detect cancers for which validated screening methods are currently unavailable, including pancreatic, liver, and ovarian cancers.

At the same time, it is important to emphasize that MCED testing should not be regarded as a replacement for established screening programs. It can only be used as a complementary measure to existing methods, not as an alternative to them. Prescribing MCED test requires informed patient consent, including a discussion of its limitations, such as the possibility of both false-positive and false-negative results.

At present, most professional organizations, including USPSTF and ESMO, do not recommend routine use of MCED testing outside clinical trials. Its use may be considered as part of an individualized approach, primarily within specialized centers or research programs.

Currently, indications for MCED testing remain limited and should be determined on the basis of individual cancer risk, availability of follow-up diagnostic evaluation, and the capacity to interpret test results. Their widespread adoption is possible only after convincing data on their impact on clinical outcomes have been obtained.

Interpretation of MCED Test Results: Positive, Negative, and Indeterminate Findings

Interpretation of MCED test results is a critical step that determines the subsequent diagnostic strategy. Unlike conventional screening methods, MCED tests do not identify a specific tumor directly; rather, they estimate the probability that a malignant process is present and, in some cases, predict the most likely tissue of origin. Interpretation requires a specialized approach and close collaboration among clinicians from multiple disciplines.

• A positive MCED test result indicates the presence of a tumor-associated molecular signal in circulating DNA. Despite very high specificity (> 99 percent), a positive result does not establish a diagnosis of cancer and must always be confirmed. Even with this level of specificity, widespread population-based testing may generate a substantial absolute number of false-positive results. No standardized diagnostic algorithm currently exists for the evaluation of patients following a positive MCED result, which may contribute to variability in clinical management. Subsequent evaluation includes targeted diagnostic investigations using imaging modalities (CT, MRI, and PET/CT), followed by histopathologic confirmation whenever indicated. Important information about the tumor’s presumed location plays a key role, as it helps reduce the scope of the examination and increase its efficiency.
• A negative result does not exclude the presence of malignancy, particularly in early-stage disease. This is due to the low concentration of ctDNA and the reduced sensitivity of current tests for detecting small tumors. Therefore, a negative result should not lead to cancellation or postponement of recommended standard screening procedures. Patients should continue to participate in recommended screening programs appropriate for their age and individual risk profile.
• Indeterminate or equivocal results occur less frequently but present the greatest challenge for clinicians. These findings may result from technical aspects of the tests, low-level molecular signals, or biological factors, including clonal hematopoiesis of indeterminate potential (CHIP), which may produce mutations in cfDNA that are unrelated to malignancy. In such cases, repeat testing or follow-up monitoring is recommended.

A fundamental principle is that clinical decisions should never be based solely on the results of an MCED test. Test findings must always be interpreted within the broader context of the patient’s clinical presentation, risk factors, and the results of other diagnostic evaluations. The optimal approach is a multidisciplinary model involving a medical oncologist, radiologist, and molecular diagnostics specialist.

In clinical practice, interpretation of MCED test results requires careful clinical judgment, as both positive and negative findings have inherent limitations and should always be considered as part of a comprehensive diagnostic assessment.

The Role of MCED Tests in Cancer Screening: Future Prospects and Unresolved Issues

The integration of MCED tests into cancer screening programs is a potential transition from traditional organ-specific screening toward a more comprehensive approach to the early detection of malignant neoplasms. However, their role remains unclear and continues to be the subject of active discussion within the oncology community.

Conventional Screening Versus MCED Testing

Established cancer screening programs (mammography, cervical cytology-based screening, colorectal cancer screening, and lung CT in high-risk individuals) have demonstrated reductions in cancer-specific mortality and are supported by evidence from randomized controlled trials. By contrast, MCED tests currently lack comparable evidence demonstrating improvements in clinical outcomes. The available data primarily demonstrate diagnostic accuracy, but do not confirm an effect on overall or cancer-specific survival.

A potential advantage of MCED testing is its ability to detect malignancies for which no effective screening methods currently exist. This is particularly relevant for pancreatic, liver, and ovarian cancers, where early diagnosis remains a major clinical challenge. Furthermore, a single test capable of detecting multiple malignancies could theoretically improve patient adherence to screening and simplify the organization of preventive programs.

Nevertheless, several important unresolved issues remain. These include the risks of overdiagnosis, detection of clinically insignificant tumors, and the resulting increase in unnecessary diagnostic procedures. Even with very high specificity, a small false-positive rate at the population level can translate into a substantial burden on healthcare system. In addition, the optimal screening interval and the appropriate target populations have yet to be determined.

Cost-Effectiveness and Clinical Trials

The cost-effectiveness of MCED testing also requires further evaluation. The high cost of tests and subsequent diagnostic procedures may limit their use, especially in settings with scarce resources. Another important consideration is the development of standardized clinical pathways for managing patients with positive MCED results.

Several large prospective studies are currently underway (including the PATHFINDER study and the NHS-Galleri trial) with the objective of determining the impact of MCED testing on clinical outcomes and the organization of cancer screening programs. Their results will be decisive in shaping recommendations and the potential implementation of these technologies into routine practice.

Comparison of MCED Testing and Conventional Cancer Screening

Accordingly, MCED tests represent a promising advance in cancer screening; however, their widespread implementation will depend on robust evidence demonstrating reductions in mortality, acceptable cost-effectiveness, and clearly defined clinical strategies for their appropriate use.

Find more scientifically accurate content on our social media

Subscribe and don’t miss out the latest resources

Clinical Significance and Future Applications of MCED Testing

MCED testing represents one of the most promising developments in modern oncology, integrating advances in molecular diagnostics, genomics, and bioinformatics. Its principal advantage lies in the ability to detect multiple cancer types simultaneously using a minimally invasive approach, thereby potentially extending the reach of early cancer detection beyond the capabilities of existing screening programs.

At the same time, currently available evidence highlights several important limitations, including variable sensitivity for early-stage disease, the absence of proven reductions in cancer-related mortality, and the need for confirmatory diagnostic evaluation following positive test results. Additional challenges include the risks of overdiagnosis, interpretation of indeterminate findings, and the organization of appropriate diagnostic assessment.

At the present time, MCED tests should not be considered a replacement for established cancer screening methods and should be used primarily within the context of clinical trials or as part of individualized approach. Their implementation in clinical practice will depend on the availability of convincing evidence of clinical benefit, the development of standardized clinical algorithms, and demonstration of cost-effectiveness.

In summary, MCED technologies have the potential to transform the paradigm of cancer screening. However, their ultimate role in clinical practice will be determined by the results of ongoing prospective clinical trials and accumulation of long-term data.